扎鲁司特联合舒利迭治疗儿童支气管哮喘临床疗效及对肺功能的影响

目的探讨扎鲁司特联合舒利迭对支气管哮喘患儿临床疗效及肺功能的影响。方法 80例哮喘患儿随机分为治疗组41例和对照组39例,对照组患儿吸入舒利迭;治疗组患儿在吸入舒利迭的基础上,口服白三烯拮抗剂扎鲁司特,2组疗程均为4周。评定治疗前后2组患儿临床疗效及肺功能改变情况。结果治疗组总有效率为90.2%,对照组总有效率为74.4%,2组差异有统计学意义(P<0.05);治疗后2组支气管哮喘患儿肺功能FEV1(实测值/预测值)、PEF(实测值/预测值)较治疗前均改善,差异有统计学意义(P<0.05);且治疗组支气管哮喘患儿肺功能FEV1(实/预)、PEF(实/预)改善较对照组明显,差异有统计学意义(P<0.05)。结论扎鲁司特与吸入糖皮质激素联合运用在改善哮喘患儿临床效果及肺功能的效果较单用吸入糖皮质激素更具优势,并且未见明显的不良反应。

Effect of zafirlukast combined with seretide on children bronchial asthma and lung function

Objective To explore the effect of zatirlukast combined with seretide on children bronchial asthma and lung function. Methods 80 cases of children with bronchial asthma were divided into treatment group （41 cases） and con- trol group （39 cases） randomly. The control group was given seretide, while the treatment group was added with zalirlukast based on the control group. Both groups were treated for 4 weeks. The pulmonary function and clinical curative effect in 2 groups were evaluated before and after treatment. Results The total effect rate of treatment group was 90. 2%, and it was 74. 4% in the control group,the difference was statistically significant （P 〈0.05）. After treatment,the FEV1 and PEF of 2 groups were all improved compared before treatment, the differences were statistically significant （P 〈 0.05）. The improvement of PEV1 and PEP in treatment group was better than that of the control group,and the difference was statistically significant （ P 〈 0.05 ）. Conclusion The effect of zafirlukast combined with glucocorticoid inhalation is better than single use of inhaled corticosteroids on children bronchial asthma and lung function, and there is no adverse reaction.